articleThe Lancet Diabetes & EndocrinologySep 15, 2025Closed access

Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial

SWSean WhartonPFPaula FreitasJHJøran HjelmesæthMKMaria KabischKKKristian Kandler

Novo Nordisk (Denmark) · The University of Texas Southwestern Medical Center · +3 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

46
total citations
FWCI
41.81
Percentile
100%
References
35
Citations per year

Authors

9

Topics & keywords

Topics
Keywords
  • Semaglutide
  • Obesity
  • German
  • MEDLINE
  • Diabetes mellitus
  • Clinical trial
No related works found for this paper.

Funding